Auriclosene
- Generic Name
- Auriclosene
- Drug Type
- Small Molecule
- Chemical Formula
- C4H9Cl2NO3S
- CAS Number
- 846056-87-9
- Unique Ingredient Identifier
- BKR7Y95229
- Background
Auriclosene has been used in trials studying the treatment of Impetigo, Bacterial Conjunctivitis, Asymptomatic Bacteriuria, and Adenoviral Conjunctivitis.
Efficacy Study of Auriclosene Irrigation Solution on Urinary Catheter Patency
- Conditions
- Urinary Catheter Blockage and Encrustation
- Interventions
- First Posted Date
- 2014-05-05
- Last Posted Date
- 2015-12-02
- Lead Sponsor
- NovaBay Pharmaceuticals, Inc.
- Target Recruit Count
- 140
- Registration Number
- NCT02130518
- Locations
- 🇺🇸
Lahey Hospital and Medical Clinic, Burlington, Massachusetts, United States
🇺🇸Los Amigos Research and Education Institute, Downey, California, United States
🇺🇸VA Long Beach Healthcare System, Long Beach, California, United States
Efficacy and Safety of Auriclosene (NVC-422) in the Treatment of Bacterial Conjunctivitis
- Conditions
- Bacterial Conjunctivitis
- Interventions
- First Posted Date
- 2013-06-14
- Last Posted Date
- 2015-05-28
- Lead Sponsor
- NovaBay Pharmaceuticals, Inc.
- Target Recruit Count
- 217
- Registration Number
- NCT01877694
Safety and Efficacy of Topical NVC-422 Gel in Impetigo
- First Posted Date
- 2011-06-07
- Last Posted Date
- 2011-06-07
- Lead Sponsor
- NovaBay Pharmaceuticals, Inc.
- Target Recruit Count
- 129
- Registration Number
- NCT01367314
- Locations
- 🇩🇴
Hospital Infantil Dr. Robert Reid Cabral, Santo Domingo, Dominican Republic
🇩🇴Instituto Dermatológico, Santo Domingo, Dominican Republic
Exploratory Study to Evaluate the Efficacy and Safety of CD07223 Gel in Subjects With Acne
- Conditions
- Acne
- Interventions
- First Posted Date
- 2010-04-20
- Last Posted Date
- 2021-02-18
- Lead Sponsor
- Galderma R&D
- Target Recruit Count
- 73
- Registration Number
- NCT01106807
- Locations
- 🇺🇸
J & S Studies, Bryan, Texas, United States
🇺🇸Cetero, Fargo, North Dakota, United States
🇺🇸Burke Pharmaceuticals, Hot Springs, Arkansas, United States
Safety and Efficacy Study of NVC-422 on Bacteriuria in Catheterized Patients
- Conditions
- Asymptomatic Bacteriuria
- Interventions
- First Posted Date
- 2008-10-29
- Last Posted Date
- 2011-09-12
- Lead Sponsor
- NovaBay Pharmaceuticals, Inc.
- Target Recruit Count
- 20
- Registration Number
- NCT00781339
- Locations
- 🇺🇸
Michael E. Debakey V.A. Medical Center, Houston, Texas, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.